Wen Liu1, Dattatraya Patil2, David H Howard3, Renee H Moore4, Heqiong Wang4, Martin G Sanda2, Christopher P Filson5. 1. Emory University School of Medicine, Atlanta, GA; Rollins School of Public Health, Emory University, Atlanta, GA. 2. Department of Urology, Emory University School of Medicine, Atlanta, GA. 3. Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA. 4. Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA. 5. Department of Urology, Emory University School of Medicine, Atlanta, GA; Atlanta Veterans Administration Medical Center, Decatur, GA. Electronic address: cfilson@emory.edu.
Abstract
OBJECTIVE: To assess adoption of prebiopsy prostate magnetic resonance imaging (MRI) in the United States and to evaluate factors associated with magnetic resonance imaging-guided prostate biopsy (MRI-Bx) use. Prior reports have shown improved cancer detection with MRI-Bx vs transrectal ultrasound-guided methods (transrectal ultrasound-guided biopsy [TRUS-Bx]). Population-based trends of their use and outcomes have not been previously characterized. MATERIALS AND METHODS: Using private insurance claims (2009-2015), we identified men who underwent prostate biopsy. Exposures were biopsy year and geographic region defined by metropolitan statistical area. Outcomes included biopsy type (MRI-Bx, TRUS-Bx, or transperineal biopsy) based on procedure codes and cancer detection based on a new diagnosis for prostate cancer (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] 185). Hierarchical mixed-effects multivariable regression estimated odds of undergoing MRI-Bx. RESULTS: We identified 241,681 men (mean age 57.5 ± 5.4 years) who underwent biopsy. The use of MRI-Bx rose rapidly (0.2% in 2009 to 6.5% in 2015, P <.001). Overall, 3429 men underwent MRI before biopsy, more commonly in metropolitan statistical areas (odds ratio 1.90, 95% confidence interval 1.66-2.19). In 2015, nearly 18% of men with prior negative biopsy underwent a prebiopsy MRI. Patients with prior negative biopsies were over 4 times more likely to use MRI guidance (vs no prior biopsies, odds ratio 4.63, 95% confidence interval 4.27-5.02) and had a greater chance of cancer detection with MRI-Bx (25.2%) vs TRUS-Bx (19.7%, P = .010). CONCLUSION: Among men undergoing prostate biopsy, prebiopsy prostate MRI utilization was concentrated within urban areas and among patients with prior negative biopsies, where its use was associated with superior cancer detection compared with traditional TRUS-Bx.
OBJECTIVE: To assess adoption of prebiopsy prostate magnetic resonance imaging (MRI) in the United States and to evaluate factors associated with magnetic resonance imaging-guided prostate biopsy (MRI-Bx) use. Prior reports have shown improved cancer detection with MRI-Bx vs transrectal ultrasound-guided methods (transrectal ultrasound-guided biopsy [TRUS-Bx]). Population-based trends of their use and outcomes have not been previously characterized. MATERIALS AND METHODS: Using private insurance claims (2009-2015), we identified men who underwent prostate biopsy. Exposures were biopsy year and geographic region defined by metropolitan statistical area. Outcomes included biopsy type (MRI-Bx, TRUS-Bx, or transperineal biopsy) based on procedure codes and cancer detection based on a new diagnosis for prostate cancer (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] 185). Hierarchical mixed-effects multivariable regression estimated odds of undergoing MRI-Bx. RESULTS: We identified 241,681 men (mean age 57.5 ± 5.4 years) who underwent biopsy. The use of MRI-Bx rose rapidly (0.2% in 2009 to 6.5% in 2015, P <.001). Overall, 3429 men underwent MRI before biopsy, more commonly in metropolitan statistical areas (odds ratio 1.90, 95% confidence interval 1.66-2.19). In 2015, nearly 18% of men with prior negative biopsy underwent a prebiopsy MRI. Patients with prior negative biopsies were over 4 times more likely to use MRI guidance (vs no prior biopsies, odds ratio 4.63, 95% confidence interval 4.27-5.02) and had a greater chance of cancer detection with MRI-Bx (25.2%) vs TRUS-Bx (19.7%, P = .010). CONCLUSION: Among men undergoing prostate biopsy, prebiopsy prostate MRI utilization was concentrated within urban areas and among patients with prior negative biopsies, where its use was associated with superior cancer detection compared with traditional TRUS-Bx.
Authors: Mansi M Chandra; Seth H Greenspan; Xiaoning Li; Jie Yang; Aurora D Pryor; Annie Laurie Winkley Shroyer; John P Fitzgerald Journal: Am J Clin Exp Urol Date: 2021-12-15
Authors: Alexander P Cole; Bjoern J Langbein; Francesco Giganti; Fiona M Fennessy; Clare M Tempany; Mark Emberton Journal: Br J Radiol Date: 2021-12-16 Impact factor: 3.039
Authors: Indrani Bhattacharya; Arun Seetharaman; Christian Kunder; Wei Shao; Leo C Chen; Simon J C Soerensen; Jeffrey B Wang; Nikola C Teslovich; Richard E Fan; Pejman Ghanouni; James D Brooks; Geoffrey A Sonn; Mirabela Rusu Journal: Med Image Anal Date: 2021-11-06 Impact factor: 8.545
Authors: Leonardo D Borregales; Gina DeMeo; Xiangmei Gu; Emily Cheng; Vanessa Dudley; Edward M Schaeffer; Himanshu Nagar; Sigrid Carlsson; Andrew Vickers; Jim C Hu Journal: J Natl Cancer Inst Date: 2022-07-11 Impact factor: 11.816
Authors: Adam Kinnaird; Wayne Brisbane; Lorna Kwan; Alan Priester; Ryan Chuang; Danielle E Barsa; Merdie Delfin; Anthony Sisk; Daniel Margolis; Ely Felker; Jim Hu; Leonard S Marks Journal: Can Urol Assoc J Date: 2022-03 Impact factor: 2.052
Authors: Samuel Carbunaru; Oluwarotimi S Nettey; Pooja Gogana; Irene B Helenowski; Borko Jovanovic; Maria Ruden; Courtney M P Hollowell; Roohollah Sharifi; Rick A Kittles; Edward Schaeffer; Peter Gann; Adam B Murphy Journal: BMC Urol Date: 2019-11-27 Impact factor: 2.264